Abstract P302 Table 1 Bed day cost of in-patient stay post section 5 for patients initiated on HMV

		<5 days: Group 1 n = 5	>5 days: Group 2 n = 7
Length of stay once declared medically fit for discharge			
Neuromuscular disease (%)		80	71
	Mean	205 (0–820)	6,172 (2,460–10,455)
Cost of stay once declared medically fit (£)			
	Total	1,025	43,205
		0	4270
	Mean		(0–12,810)
Cost of HDU readmission (£)	Total	0	29,890
Total cost (£)		1,025	73,095
In-patient Mortality (%)		0	86

Results Twelve patients were identified and separated into 2 groups according to LoS: less than 5 days (group 1; n = 5) or greater than 5 days (group 2; n = 7).

Various primary diagnoses were represented in each group. The main variable separating groups was pre-admission social status. Patients with a live-in carer, willing spouse or established 24-hour care were discharged back to their original home within 4 days of being declared medically fit. Those without such care had an average LoS of 27.4 days (17–51), with a large increase in associated cost and mortality. (Table 1). All patients in Group 1 survived and were successfully discharged. The in-hospital mortality for patients in Group 2 was 86%.

Discussion HMV is a complex modality requiring specialist training to facilitate home use. Patients unable to manage HMV independently have significant care needs. This study showed that patients who do not have an established care network pre-discharge have an increased LoS and higher mortality. The current Continuing Healthcare process and Social Services structure is not robust enough to meet these patients' needs.

REFERENCES

- European Respiratory Journal. 2005;25(6):1025-1031
- Rello J, et al. *Chest*. 2010;137(5):1138-1144

P303 DOES REGULAR SURVEILLANCE ENSURE THE OPPORTUNITY OF NON-INVASIVE VENTILATION TO PATIENTS WITH MOTOR NEURONE DISEASE?

F Thaivalappil, B Kathiresan, M Davies, I Smith. *Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge CB23 3RE*

10.1136/thoraxjnl-2014-206260.421

Introduction Most people with motor neurone disease (MND) die from respiratory failure and non-invasive ventilation (NIV) can improve survival. The median survival of patients with good bulbar function not treated with NIV was just 11 days in one RCT (1). We wished to establish whether our 3 monthly follow up regime, following NICE guidance (2), ensures all patients are offered NIV or whether many are dying without this treatment opportunity.

Aim Establish what proportion of patients died before NIV was offered while under our follow up.

Method A retrospective analysis of case notes of patients who died during the calendar year 2013. Survival was calculated as days (d) from starting of NIV until death.

Abstract P303 Figure 1 Kaplan-Meier curve showing survival in NIV compliant group

Results From our cohort, 24 patients died in 2013 of whom 20 had been offered NIV (17 compliant). Median survival was 390 (IQR 147–798) d. Median survival for NIV compliant patients was 462 (IQR 223–848) d. Median survival was 190 d for the 2 NIV compliant patients with severe bulbar dysfunction and 85 days for 3 patients who were non-compliant with NIV.

Of the 4 patients who died before NIV was offered, 2 had severe bulbar dysfunction and 1 patient was on CPAP for treatment of obstructive sleep apnoea. Pneumonia was reported as the cause of death in 2 of these patients. Details of the mode of dying of the other 2 patients could not be established (certified as MND).

Conclusion Most of the patients dying with MND had been offered NIV, 85% were compliant with treatment and survival was at least as good as published results. 4 died before NIV was offered but in 2, death was precipitant due to pneumonia, not ventilatory failure. As a default, 3 monthly review seems a reasonably safe interval for ventilatory surveillance in people with MND balancing intrusive hospital visits with the risk of missing the opportunity to try NIV at the end of life.

REFERENCES

- Bourke SC, et al. *Lancet neurol*. 2006; 5: 140-7
- NICE guidelines (CG105). 2010. Use of NIV in the management of MND

P304 COMPLICATIONS RELATED TO TRACHEOSTOMY TUBE CHANGE: EVALUATION OF PRACTICE

B Kathiresan, T Quinnell, K Slack. *Papworth Hospital NHS Trust, Cambridge, UK*

10.1136/thoraxjnl-2014-206260.422

Introduction and objectives Tracheostomy tubes are used outside intensive care unit in a variety of settings. Tracheostomy tube change is a potentially high risk procedure with life threatening complications attached to it. The Respiratory Sleep and Support Centre (RSSC) at Papworth Hospital specialises in weaning patients from prolonged invasive ventilation and providing domiciliary invasive and non-invasive ventilatory support. Tracheostomy tube change is regularly undertaken for both patient groups. Review of our current clinical practice and complications related to this procedure was needed due to the risks involved.

Moderated posters

Methods We conducted a prospective observational study of tracheostomy tube changes for patients admitted from home and those weaning from invasive ventilation in our unit. Data were collected from February to May 2014.

Results Eighteen patients receiving domiciliary tracheostomy ventilation attended during the study period. Eight patients had silver tubes, 7 had plastic cuffed tubes with inner cannulae and 1 had a plastic uncuffed tube with inner cannula. Two weaning patients were included and underwent five tracheostomy changes between them.

Data were obtained for 34 tube changes during the study period. Thirty were routine tube changes and 4 were expedited for reasons including stomal leak and partial dislodgement. Plastic tubes with inner cannulae were changed in accordance with the European Economic Community directive (1), with a mean of 28 days between tube changes. Sixteen (47%) were undertaken by consultant and 18 (53%) by trainee physician.

There were no complications in 31 (91%) tube changes. Three had minor complications such as minor bleeding and one patient who receives 24 hr home tracheostomy ventilation needed bagging and suction to clear secretions. Bronchoscopy was performed in 30 (88%) following tube change to clear respiratory secretions, check tube position and sometimes in response to a difficult tube insertion.

Conclusion No major complications occurred during the study period. This is probably because the procedure is undertaken by experienced personnel in a controlled environment. The threshold for post procedure bronchoscopy appears to be low and we are currently reviewing this aspect of our practice.

REFERENCE

- 1 Intensive care society. Standards for the care of adult patients with temporary tracheostomy. 2008

Tackling tuberculosis

M35 ADVERSE EFFECTS OF LATENT TUBERCULOSIS TREATMENT IN MIGRANTS

EK Denny, VM Macavei, S Rolls, C Ma, NP Jayasekera, TC O'Shaughnessy, VLC Potter, VLC White, H Kunst. *Barts Health NHS Trust, London, UK*

10.1136/thoraxjnl-2014-206260.423

Background Most cases of tuberculosis (TB) in the UK occur in migrants. The majority develop active TB within 5 years of arriving in the UK, usually due to reactivation from latent tuberculosis infection (LTBI). Therefore identifying and treating LTBI in migrants who are at risk of reactivation, is critical to reduce rates of active TB. It is, however, unclear if migrants develop any significant adverse effects from chemoprophylaxis (Rifampicin and Isoniazid), which subsequently affects adherence.

Aim To assess the type and frequency of adverse effects in migrants on treatment for LTBI.

Methods A retrospective study was conducted within our Trust between 1st January 2007 and 31st December 2012. Records of patients between the ages of 16–35, who had lived in the country for less than 5 years and received chemoprophylaxis, were examined.

Results 472 patients treated for LTBI were included. Mean age was 30.4 ± 7.4 years and 54.8%(259) were males. Ethnic origin included: Indian subcontinent 327(69.3%), African 113(24%),

Caucasian 14(3%) and other 18(3.8%). Hepatitis B was detected in 5 cases (1%), hepatitis C in 2 cases (0.4%) and HIV was present in 1 case (0.2%). 19(4%) patients experienced adverse effects. 13(2.7%) reported gastrointestinal symptoms (nausea, vomiting), 4(0.8%) developed a skin rash and there was 1(0.2%) case of thrombocytopenia. Three of the 4 cases who developed a skin rash stopped ATT, and all three patients developed active TB two to four years later. One patient developed peripheral neuropathy due to Isoniazid. Drug induced hepatitis with a rise in ALT greater than three times the upper limit of normal was present in 15 patients (3.1%). An increase in bilirubin level greater than two times normal was recorded in 5 patients (1%). One patient who had concurrent hepatitis B was hospitalised due to hepatotoxicity.

Conclusion Treatment for LTBI in migrants below the age of 35 is safe, associated with a low risk of hepatotoxicity and should be feasible in primary care. Adverse effects should be managed promptly to ensure treatment adherence and prevention of progression to active TB.

M36 EVALUATING AEROSOL ADMINISTRATION OF A CANDIDATE TB VACCINE MVA85A

¹Z Manjaly Thomas, ¹I Satti, ¹S Harris, ¹J Meyer, ¹S Sheehan, ²H Bettinson, ¹H McShane. ¹University of Oxford, Oxford, England, UK; ²Oxford University Hospitals NHS Trust, Oxford, England, UK

10.1136/thoraxjnl-2014-206260.424

There is an urgent need for a better vaccine against TB than BCG, which confers variable protection against pulmonary TB, the main source of TB transmission.

Heterologous prime-boost vaccination regimens using virally-vectored vaccines induce strong cellular immune responses and are a leading strategy for TB vaccine development. Boosting BCG with MVA85A, a recombinant viral vector expressing antigen 85A, can enhance BCG induced protection in animal models. MVA85A in humans is safe and immunogenic when administered systemically.

Animal data suggests delivering a vaccine to the respiratory mucosa may be the most protective route. We recently completed the first trial where a virally-vectored vaccine, MVA85A, was delivered to humans by aerosol; and was found to be safe and highly immunogenic. This route also has potential for dose-sparing.

A limitation of virally-vectored vaccines is anti-vector immunity, which limits use and re-use.

Non-human primate data with aerosolised MVA85A suggests that aerosol vaccination induces less systemic anti-vector immunity than systemic routes. We have demonstrated this is also true in humans in our first aerosol trial, where humoral anti-vector immunity to MVA was induced by volunteers vaccinated by the systemic route but not the aerosol route.

An on-going trial now addresses the question, if alternating routes of vaccination can abrogate anti-vector immunity, by immunising twice with MVA85A by heterologous routes one month apart.

This would be an important development for the development of aerosolised TB vaccines but also for new vectored vaccines for RSV, universal influenza and a range of bacterial respiratory pathogens.